How this orthopedic surgeon predicts Ozempic will disrupt the industry

Orthopedic

Ozempic and Wegovy have become as recognizable as brands like McDonalds and Amazon. But what will these drugs' popularity mean for the orthopedic industry? 

Thomas DeBerardino, MD, a sports medicine orthopedic surgeon at UT Health San Antonio, connected with Becker's to answer, "How do you think the popularity of glucagon-like peptide-1 receptor agonists such as Ozempic and Wegovy will affect the orthopedic industry?"

Ask Orthopedic Surgeons is a weekly series of questions posed to surgeons around the country about clinical, business and policy issues affecting orthopedic care. We invite all orthopedic surgeon and specialist responses.

Next question: What was the smartest move you made in 2023?

Please send responses to Riz Hatton at rhatton@beckershealthcare.com by 5 p.m. CST Thursday, Dec. 14.

Note: This response has been lightly edited for length and clarity.

Dr. Thomas DeBerardino: GLP-1 receptor agonists such as Ozempic and Wegovy will be a positive disruptive force in the orthopedic industry, by providing a new way to better control Type 2 diabetes. GLP-1 receptor agonists such as these have also been shown to reduce fracture risk in this subset of patients. Reducing hip fractures (by almost 40% in one study) in patients with Type 2 diabetes would be an incredible secondary benefit.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers